首页> 外文期刊>Future microbiology >Differential diagnostic assays for discriminating mycobacteria, especially for nontuberculous mycobacteria: what does the future hold?
【24h】

Differential diagnostic assays for discriminating mycobacteria, especially for nontuberculous mycobacteria: what does the future hold?

机译:鉴别诊断分枝杆菌特别是非结核分枝杆菌的鉴别诊断方法:未来将如何发展?

获取原文
获取原文并翻译 | 示例
       

摘要

Mycobacteria infections are an important medical problem, and many are regarded as emerging and re-emerging diseases. Mycobacterium tuberculosis, the causative agent of tuberculosis, remains a leading cause of human morbidity and mortality worldwide, with approximately 8.6 million cases and 1.3 million deaths in 2012. In addition, the incidence of nontuberculous Mycobacterium infection has significantly increased, especially among developed countries. Although phenotypical appearances such as culture characteristics and/or susceptibility to anti-Mycobacterium drugs are variable between different mycobacterial species, early diagnosis is crucial in terms of patient treatment and clinical outcome. In this manuscript, we describe the development of diagnostic techniques, from the classical/conventional to the most recent advances, and provide an overview of the future direction of discrimination procedures.
机译:分枝杆菌感染是重要的医学问题,许多分枝杆菌感染被视为正在出现和正在重新出现的疾病。结核分枝杆菌是结核病的致病因素,仍然是全世界人类发病和死亡的主要原因,2012年约有860万例,死亡130万人。此外,非结核性分枝杆菌感染的发生率显着增加,特别是在发达国家中。尽管表型的出现,例如培养特性和/或对抗分枝杆菌药物的敏感性在不同的分枝杆菌物种之间是可变的,但就患者治疗和临床结果而言,早期诊断至关重要。在本手稿中,我们描述了从经典/传统到最新进展的诊断技术的发展,并概述了歧视程序的未来方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号